Title

Dose-finding Study to Evaluate Immunogenicity of Three Different Dose Levels of the IMVAMUNE (MVA-BN) Smallpox Vaccine.
Phase II, Double-blind, Randomised, Dose-finding Study to Evaluate the Immunogenicity of Three Different Doses of MVA-BN Smallpox Vaccine in 18-30 Year Old Smallpox naïve Healthy Subjects
  • Phase

    Phase 2
  • Study Type

    Interventional
  • Status

    Completed No Results Posted
  • Study Participants

    165
The objective of the study is to find the optimal dose for the smallpox candidate vaccine IMVAMUNE (MVA-BN). For this purpose the study compares IMVAMUNE (MVA-BN) administered at three different dose levels.
Study Started
Apr 30
2003
Primary Completion
Nov 30
2003
Study Completion
Dec 31
2005
Last Update
Jan 10
2019

Biological IMVAMUNE (MVA-BN)

Two vaccinations of 0.5 ml MVA-BN vaccine, separated by a 4 week interval.

Group 1 Active Comparator

healthy, vaccinia naïve subjects 2 x 10E7 TCID50 IMVAMUNE (MVA-BN), subcutaneous

Group 2 Active Comparator

healthy, vaccinia naïve subjects 5 x 10E7 TCID50 IMVAMUNE (MVA-BN), subcutaneous

Group 3 Active Comparator

healthy, vaccinia naïve subjects 1 x 10E8 TCID50 IMVAMUNE (MVA-BN), subcutaneous

Criteria

Inclusion Criteria:

Healthy male and female subjects, aged 18 - 30 years
Signed informed consent after being advised of the risks and benefits of the study in a language able to understand, and prior to performance of any study specific procedure.
Free of obvious health problems with acceptable medical history by screening evaluation and physical examination.
Subject of not of child-bearing potential or all of the following: A urine/serum ß-HCG pregnancy test gives a negative result, use of adequate contraceptive precautions for 30 days before first vaccination.

Exclusion Criteria:

Known or suspected history of smallpox vaccination or typical vaccinia scar.
Positive test result in MVA specific ELISA or PRNT at screening.
Positive result in HIV or HCV antibody test at screening.
HbsAG positive at screening.
Pregnancy or breast-feeding.
Uncontrolled serious infection i.e. not responding to antimicrobial therapy
History of any serious medical condition, which in the opinion of the investigator, would compromise the safety of the subject.
History of autoimmune disease
History of malignancy.
History of chronic alcohol abuse and/or intravenous drug abuse.
History of allergic disease or reactions likely to be exacerbated by any component of the vaccine.
History of anaphylaxis or severe allergic reaction.
Acute disease (a moderate or severe illness with or without a fever) at the time of enrolment.
Any vaccinations within a period starting 30 days prior to administration of the vaccine and ending at study conclusion.
Chronic administration of immuno-suppressants or other immune-modifying drugs.
Administration or planned administration of immunoglobulins and/or any blood products during the study period.
Use of any investigational or non-registered drug or vaccine.
No Results Posted